Log in

Cara Therapeutics News Headlines (NASDAQ:CARA)

$17.78
+0.53 (+3.07 %)
(As of 02/18/2020 06:00 AM ET)
Today's Range
$17.15
Now: $17.78
$17.81
50-Day Range
$15.02
MA: $16.43
$17.78
52-Week Range
$14.77
Now: $17.78
$27.55
Volume485,248 shs
Average Volume474,131 shs
Market Capitalization$711.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26

Headlines

Cara Therapeutics (NASDAQ CARA) News Headlines

Source:
DateHeadline
Cara Therapeutics Inc (NASDAQ:CARA) Expected to Announce Earnings of -$0.62 Per ShareCara Therapeutics Inc (NASDAQ:CARA) Expected to Announce Earnings of -$0.62 Per Share
www.americanbankingnews.com - February 17 at 4:36 AM
Cara Therapeutics Inc (NASDAQ:CARA) Short Interest UpdateCara Therapeutics Inc (NASDAQ:CARA) Short Interest Update
www.americanbankingnews.com - February 14 at 7:42 PM
Cara Therapeutics, Inc. Common Stock (CARA) After-Hours QuotesCara Therapeutics, Inc. Common Stock (CARA) After-Hours Quotes
www.nasdaq.com - February 12 at 4:12 PM
Cara Therapeutics, Inc. Common Stock (CARA) Real-Time QuotesCara Therapeutics, Inc. Common Stock (CARA) Real-Time Quotes
www.nasdaq.com - February 12 at 4:12 PM
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral FormulationCara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation
www.bloomberg.com - February 11 at 5:30 PM
Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Salary Reflect Performance?Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Salary Reflect Performance?
finance.yahoo.com - February 3 at 7:54 AM
Cara Therapeutics Inc (NASDAQ:CARA) Given Consensus Recommendation of "Buy" by BrokeragesCara Therapeutics Inc (NASDAQ:CARA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 29 at 3:42 AM
Cara Therapeutics Inc (NASDAQ:CARA) Expected to Post Quarterly Sales of $5.58 MillionCara Therapeutics Inc (NASDAQ:CARA) Expected to Post Quarterly Sales of $5.58 Million
www.americanbankingnews.com - January 27 at 3:02 AM
Cara Therapeutics Inc (NASDAQ:CARA) Expected to Post Earnings of -$0.62 Per ShareCara Therapeutics Inc (NASDAQ:CARA) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - January 25 at 1:10 PM
Trevi Therapeutics: A Promising Pruritus Player In 2020Trevi Therapeutics: A Promising Pruritus Player In 2020
seekingalpha.com - January 15 at 10:27 PM
Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceCara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 8:59 PM
Cara Therapeutics: Recent Stock Price Plunge Was A Bit ExaggeratedCara Therapeutics: Recent Stock Price Plunge Was A Bit Exaggerated
seekingalpha.com - December 18 at 5:46 PM
Cara Therapeutics Announces Equity Grants to Employees Under Inducement PlanCara Therapeutics Announces Equity Grants to Employees Under Inducement Plan
finance.yahoo.com - December 6 at 7:50 PM
Pruritus Therapeutics 2019 Market Estimation, Dynamics, Outllook, Research, Trends and Forecasts to 2026Pruritus Therapeutics 2019 Market Estimation, Dynamics, Outllook, Research, Trends and Forecasts to 2026
www.marketwatch.com - December 4 at 9:19 AM
Investors Who Bought Cara Therapeutics (NASDAQ:CARA) Shares Three Years Ago Are Now Up 78%Investors Who Bought Cara Therapeutics (NASDAQ:CARA) Shares Three Years Ago Are Now Up 78%
finance.yahoo.com - December 4 at 9:19 AM
BRIEF-Cara Therapeutics Reports Data From Phase 2 Trial Of KorsuvaBRIEF-Cara Therapeutics Reports Data From Phase 2 Trial Of Korsuva
www.msn.com - December 3 at 10:52 PM
Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare ConferenceCara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - December 3 at 5:51 PM
Why Cara Therapeutics Stock Is Plunging TodayWhy Cara Therapeutics Stock Is Plunging Today
www.fool.com - December 3 at 12:51 PM
Cara Therapeutics down 19% premarket on mixed results from Korsuva studyCara Therapeutics down 19% premarket on mixed results from Korsuva study
seekingalpha.com - December 3 at 7:50 AM
Cara Therapeutics announces positive results in trial of treatment for chronic kidney diseaseCara Therapeutics announces positive results in trial of treatment for chronic kidney disease
www.msn.com - December 3 at 7:50 AM
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe PruritusCara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus
finance.yahoo.com - December 3 at 7:50 AM
UPDATE: Cara Therapeutics announces positive results in trial of treatment for chronic kidney diseaseUPDATE: Cara Therapeutics announces positive results in trial of treatment for chronic kidney disease
finance.yahoo.com - December 3 at 7:50 AM
Is Cara Therapeutics a Buy?Is Cara Therapeutics a Buy?
www.nasdaq.com - November 21 at 7:23 AM
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?
finance.yahoo.com - November 13 at 1:25 PM
Cara Therapeutics to Present at November Investor ConferencesCara Therapeutics to Present at November Investor Conferences
finance.yahoo.com - November 12 at 6:52 PM
BRIEF-Cara Therapeutics Announces Publication Of Difelikefalin KALM-1 Phase 3 Trial ResultsBRIEF-Cara Therapeutics Announces Publication Of Difelikefalin KALM-1 Phase 3 Trial Results
www.msn.com - November 11 at 11:31 PM
Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of MedicineCara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine
finance.yahoo.com - November 11 at 8:29 AM
Cara Therapeutics Q3 Update: Forget the Financials and Focus on the PipelineCara Therapeutics Q3 Update: Forget the Financials and Focus on the Pipeline
www.fool.com - November 6 at 6:55 AM
Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMTEdited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMT
finance.yahoo.com - November 6 at 6:55 AM
Cara Therapeutics EPS misses by $0.16, beats on revenueCara Therapeutics EPS misses by $0.16, beats on revenue
seekingalpha.com - November 5 at 5:28 PM
Cara Therapeutics Reports Third Quarter 2019 Financial ResultsCara Therapeutics Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 5 at 5:28 PM
Cara Therapeutics Announces Presentations at Kidney Week 2019Cara Therapeutics Announces Presentations at Kidney Week 2019
finance.yahoo.com - November 1 at 8:41 AM
Cara Therapeutics to Announce Third Quarter 2019...Cara Therapeutics to Announce Third Quarter 2019...
www.benzinga.com - October 29 at 6:44 PM
Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - October 29 at 1:44 PM
Here’s What Hedge Funds Think About Casa Therapeutics Inc (CARA)Here’s What Hedge Funds Think About Casa Therapeutics Inc (CARA)
finance.yahoo.com - October 28 at 11:11 PM
Have Insiders Been Selling Cara Therapeutics, Inc. (NASDAQ:CARA) Shares?Have Insiders Been Selling Cara Therapeutics, Inc. (NASDAQ:CARA) Shares?
finance.yahoo.com - October 20 at 1:56 PM
Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with PruritusCara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
finance.yahoo.com - October 14 at 12:00 PM
First cannabis cafe in the U.S. opens in Los AngelesFirst cannabis cafe in the U.S. opens in Los Angeles
finance.yahoo.com - October 3 at 3:35 PM
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare ConferenceCara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 26 at 8:34 PM
How Much Of Cara Therapeutics, Inc. (NASDAQ:CARA) Do Institutions Own?How Much Of Cara Therapeutics, Inc. (NASDAQ:CARA) Do Institutions Own?
finance.yahoo.com - September 19 at 11:46 AM
Pruritus Therapeutics Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast 2026Pruritus Therapeutics Market Is Estimated To Expand At a Healthy CAGR in the Upcoming Forecast 2026
www.marketwatch.com - September 10 at 3:54 PM
Pruritus Drug Market - Cara Therapeutics, Enteris BioPharma, NeRRe Therapeutics, Menlo Therapeutics, XBiotech, Ipsen Pharma, Novus TherapeuticsPruritus Drug Market - Cara Therapeutics, Enteris BioPharma, NeRRe Therapeutics, Menlo Therapeutics, XBiotech, Ipsen Pharma, Novus Therapeutics
www.marketwatch.com - August 28 at 11:52 AM
Cara Therapeutics Inc (CARA) Q2 2019 Earnings Call TranscriptCara Therapeutics Inc (CARA) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 21 at 8:22 PM
Cara in-licenses oral formulation of Enteris Bios PeptelligenceCara in-licenses oral formulation of Enteris Bio's Peptelligence
seekingalpha.com - August 21 at 11:43 AM
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation TechnologyCara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology
finance.yahoo.com - August 21 at 11:43 AM
Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™
finance.yahoo.com - August 21 at 11:43 AM
Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Pay Reflect Performance?Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Pay Reflect Performance?
finance.yahoo.com - August 19 at 3:13 PM
Calming and Sleeping Market to Make Great Impact in Near Future by 2025Calming and Sleeping Market to Make Great Impact in Near Future by 2025
www.marketwatch.com - August 16 at 3:11 PM
Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMTEdited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT
finance.yahoo.com - August 8 at 12:56 PM
Cara Therapeutics EPS beats by $0.03, beats on revenueCara Therapeutics EPS beats by $0.03, beats on revenue
seekingalpha.com - August 7 at 8:31 PM
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel